Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Here's Why Merck (MRK) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Moderna (MRNA) Up More Than 30% in 10 Days: What Lies Ahead?

Moderna's (MRNA) shares are rising presumably in anticipation of rising demand for its COVID-19 vaccine amid authorization for younger population and the fear of another global infection wave.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

Merck (MRK) closed the most recent trading day at $78.12, moving -0.66% from the previous trading session.

Iovance (IOVA) to Start Clinical Studies for TIL Therapy

Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.

AbbVie (ABBV) Inks Deal to Develop COVID Antiviral Treatment

AbbVie (ABBV) joins Scripps Research in the latter's SARS-CoV-2 research program to accelerate the development of new antiviral therapies for COVID-19.

Merck (MRK) Stops Keytruda-Lynparza Combo Prostate Cancer Study

Merck (MRK) decides to discontinue a late-stage prostate cancer study evaluating Keytruda in combination with AstraZeneca's Lynparza, following its failure to demonstrate a benefit in overall survival.

Nektar (NKTR) Plunges on Bempeg's Melanoma Study Failure

Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.

AstraZeneca, Merck's Lynparza Gets FDA Nod for Expanded Use

FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

Do Options Traders Know Something About Merck (MRK) Stock We Don't?

Investors need to pay close attention to Merck (MRK) stock based on the movements in the options market lately.

Mirati (MRTX) Focuses on Seeking Nod for KRAS Drug Adagrasib

Mirati's (MRTX) regulatory filing to the FDA for adagrasib in second-line NSCLC gets a longer-than-expected review period. MRTX is progressing well with the pipeline development for other candidates.

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed at $77.89 in the latest trading session, marking a +0.13% move from the prior day.

Mark Vickery headshot

Top Stock Reports for Bank of America, Qualcomm & ConocoPhillips

Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp. (BAC), Qualcomm Inc. (QCOM) and ConocoPhillips (COP).

Pfizer (PFE) Begins Pediatric Study on COVID Pill Paxlovid

Pfizer's (PFE) Paxlovid is the first oral antiviral pill to be studied in a pediatric clinical study.

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

Smart Beta ETF report for RYH

Kinjel Shah headshot

What's in Store for These 3 Big Pharma Outperformers in 2022?

J&J (JNJ), AbbVie (ABBV) and Merck (MRK) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Alpine (ALPN) Down on FDA Partial Clinical Hold on Cancer Study

The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.

FDA Nods to Bristol Myers' (BMY) Opdivo for Additional Indication

Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.

Merck (MRK) Outperforms Industry, What's in Store for 2022?

Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed at $77.83 in the latest trading session, marking a +0.88% move from the prior day.

Ekta Bagri headshot

WHO Recommends Merck (MRK) Oral Pill for Certain COVID Patients

Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.

Nektar (NKTR) Q4 Earnings Top, Three Bempeg Filings Due in 2022

Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates

Mirati Therapeutics (MRTX) reports wider-than-expected fourth-quarter loss. Sales miss estimates.